Hikma has set out expected enhancements to its injectables business, following the completion of its recent agreement to acquire a bundle of US finished-dose assets from Xellia Pharmaceuticals following clearance under applicable US antitrust laws.
As a result of the deal – which saw Hikma agree to pay cash consideration of $135m, subject to customary adjustments, with additional contingent consideration of up to $50m payable upon achievement of certain regulatory and commercial milestones (see sidebar) –